Literature DB >> 11948045

Noninvasive positive-pressure ventilation vs. conventional oxygen supplementation in hypoxemic patients undergoing diagnostic bronchoscopy.

Massimo Antonelli1, Giorgio Conti, Monica Rocco, Andrea Arcangeli, Franco Cavaliere, Rodolfo Proietti, Gianfranco Umberto Meduri.   

Abstract

OBJECTIVE: We have reported previously on the use of noninvasive positive-pressure ventilation (NPPV) to assist spontaneous breathing in high-risk hypoxemic patients (i.e., PaO(2)/fraction of inspired oxygen [FIO(2)] ratio, < or = 100) who are undergoing diagnostic fiberoptic bronchoscopy (FOB). The efficacy of this intervention in patients with less severe forms of hypoxemia (i.e., PaO(2)/FIO(2) ratio, < 200) is unknown. PATIENTS AND METHODS: Twenty-six patients with PaO(2)/FIO(2) ratios < or = 200 who required bronchoscopic BAL for suspected nosocomial pneumonia were entered into the study. Thirteen patients were randomized during FOB to receive NPPV, and 13 patients were randomized to receive conventional oxygen supplementation by Venturi mask. The primary end points were changes in the PaO(2)/FIO(2) ratio during FOB and within 60 min of terminating the procedure. RESULTS AND OUTCOME: At study entry, the two groups were similar in terms of age, simplified acute physiologic score II values, and cardiorespiratory parameters. During FOB, the mean (+/- SD) PaO(2)/FIO(2) ratio increased by 82% in the NPPV group (261 +/- 100 vs 139 +/- 38; p < 0.001) and decreased by 10% in the conventional oxygen supplementation group (155 +/- 24 to 139 +/- 38; p = 0.23). Sixty minutes after undergoing FOB, the NPPV group had a higher mean PaO(2)/FIO(2) ratio (176 +/- 62 vs 140 +/- 38; p = 0.09), a lower mean heart rate (91 +/- 18 vs. 108 +/- 15 beats/min; p = 0.02), and no reduction in mean arterial pressure in comparison to a 15% decrease from the baseline in the control group. One patient in the NPPV group and two patients in the control group required nonemergent intubation. Major bacterial isolates included Staphylococcus aureus (7 of 30 isolates; 23%) and Pseudomonas aeruginosa (12 of 30 isolates; 40%).
CONCLUSION: In patients with severe hypoxemia, NPPV is superior to conventional oxygen supplementation in preventing gas-exchange deterioration during FOB with better hemodynamic tolerance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948045     DOI: 10.1378/chest.121.4.1149

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Determination of Factors Affecting Mortality of Patients with Sepsis in a Tertiary Intensive Care Unit.

Authors:  Baran Balcan; Şehnaz Olgun; Fatih Torlak; Seda Beyhan Sağmen; Emel Eryüksel; Sait Karakurt
Journal:  Turk Thorac J       Date:  2015-07-01

2.  Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting.

Authors:  Sean P Keenan; Tasnim Sinuff; Karen E A Burns; John Muscedere; Jim Kutsogiannis; Sangeeta Mehta; Deborah J Cook; Najib Ayas; Neill K J Adhikari; Lori Hand; Damon C Scales; Rose Pagnotta; Lynda Lazosky; Graeme Rocker; Sandra Dial; Kevin Laupland; Kevin Sanders; Peter Dodek
Journal:  CMAJ       Date:  2011-02-14       Impact factor: 8.262

3.  Fiberoptic bronchoscopy under noninvasive ventilation and propofol target-controlled infusion in hypoxemic patients.

Authors:  Benjamin Clouzeau; Hoang-Nam Bui; Emmanuelle Guilhon; Marieke Grenouillet-Delacre; Melanie Saint Leger; Tahar Saghi; Jerome Pillot; Bruno Filloux; Solenn Coz; Alexandre Boyer; Frederic Vargas; Didier Gruson; Gilles Hilbert
Journal:  Intensive Care Med       Date:  2011-10-08       Impact factor: 17.440

4.  Influence of lung collapse distribution on the physiologic response to recruitment maneuvers during noninvasive continuous positive airway pressure.

Authors:  Gianmaria Cammarota; Rosanna Vaschetto; Emilia Turucz; Fabrizio Dellapiazza; Davide Colombo; Cristiana Blando; Francesco Della Corte; Salvatore Maurizio Maggiore; Paolo Navalesi
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

Review 5.  Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review.

Authors:  Laurent Papazian; Amanda Corley; Dean Hess; John F Fraser; Jean-Pierre Frat; Christophe Guitton; Samir Jaber; Salvatore M Maggiore; Stefano Nava; Jordi Rello; Jean-Damien Ricard; François Stephan; Rocco Trisolini; Elie Azoulay
Journal:  Intensive Care Med       Date:  2016-03-11       Impact factor: 17.440

6.  The feasibility and safety of fiberoptic bronchoscopy during noninvasive ventilation in patients with established acute lung injury: another small brick in the wall.

Authors:  Massimo Antonelli
Journal:  Crit Care       Date:  2011-09-30       Impact factor: 9.097

7.  Another step for noninvasive ventilation in chronic obstructive pulmonary disease patients!

Authors:  Samir Jaber; Gerald Chanques
Journal:  Crit Care       Date:  2010-06-09       Impact factor: 9.097

8.  Early fiberoptic bronchoscopy during non-invasive ventilation in patients with decompensated chronic obstructive pulmonary disease due to community-acquired-pneumonia.

Authors:  Raffaele Scala; Mario Naldi; Uberto Maccari
Journal:  Crit Care       Date:  2010-04-29       Impact factor: 9.097

9.  Safety of performing fiberoptic bronchoscopy in critically ill hypoxemic patients with acute respiratory failure.

Authors:  Christophe Cracco; Muriel Fartoukh; Hélène Prodanovic; Elie Azoulay; Cécile Chenivesse; Christine Lorut; Gaëtan Beduneau; Hoang Nam Bui; Camille Taille; Laurent Brochard; Alexandre Demoule; Bernard Maitre
Journal:  Intensive Care Med       Date:  2012-10-16       Impact factor: 17.440

10.  A prospective randomized comparative study of high-flow nasal cannula oxygen and non-invasive ventilation in hypoxemic patients undergoing diagnostic flexible bronchoscopy.

Authors:  Bancha Saksitthichok; Tananchai Petnak; Apichart So-Ngern; Viboon Boonsarngsuk
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.